This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EU biotech law should have high level of data protection, regulators say

( March 12, 2026, 10:29 GMT | Official Statement) -- MLex Summary: The EU's planned biotech law should not lower the level of data protection for clinical trial participants, two EU data protection bodies have said. In a joint statement, the European Data Protection Board and the European Data Protection Supervisor said they supported plans to harmonize clinical trials rules and introduce a single legal basis for processing personal data in the European Biotech Act. But they made a series of recommendations to protect sensitive health and genetic data, including clarifying controller codes, limiting data retention, coherence with the EU's AI law, and processing data in regulatory sandboxes.Statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections